China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data

10th April 2020 Uncategorised 0

In the global race to develop an effective vaccine to protect people against the novel coronavirus, China’s CanSino Bio has leapt ahead. The biotech has started enrollment activities of a phase 2 trial testing its recombinant shot, Ad5-nCoV, in healthy volunteers in the city of Wuhan.

More: China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data
Source: fierce